Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: an analysis of the prospective QoLiTrap study
Introduction - Colorectal cancer (CRC) mainly affects older patients. The pivotal VELOUR phase III trial of aflibercept plus FOLFIRI in metastatic CRC (mCRC) included only 5.9% of patients aged ≥75 years. Herein, we report a preplanned analysis from QoLiTrap, a large prospective observational study...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 2023
|
| In: |
Journal of geriatric oncology
Year: 2023, Volume: 14, Issue: 8, Pages: 1-10 |
| ISSN: | 1879-4076 |
| DOI: | 10.1016/j.jgo.2023.101638 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jgo.2023.101638 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1879406823002357 
|
| Author Notes: | Gudrun Piringer, Josef Thaler, Sandro Anchisi, Christine Geffriaud-Ricouard, Max Gueldner, Felicitas Scholten, Hans-Günter Derigs, Pierre Bohanes, Birgit Grünberger, Leonora Schwarz, Roger von Moos, Ralf-Dieter Hofheinz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1895740460 | ||
| 003 | DE-627 | ||
| 005 | 20241205153029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240718s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jgo.2023.101638 |2 doi | |
| 035 | |a (DE-627)1895740460 | ||
| 035 | |a (DE-599)KXP1895740460 | ||
| 035 | |a (OCoLC)1475303325 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Piringer, Gudrun |e VerfasserIn |0 (DE-588)1336132809 |0 (DE-627)1895741211 |4 aut | |
| 245 | 1 | 0 | |a Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer |b an analysis of the prospective QoLiTrap study |c Gudrun Piringer, Josef Thaler, Sandro Anchisi, Christine Geffriaud-Ricouard, Max Gueldner, Felicitas Scholten, Hans-Günter Derigs, Pierre Bohanes, Birgit Grünberger, Leonora Schwarz, Roger von Moos, Ralf-Dieter Hofheinz |
| 264 | 1 | |c November 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 28. September 2023, Artikelversion: 28. September 2023 | ||
| 500 | |a Gesehen am 18.07.2024 | ||
| 520 | |a Introduction - Colorectal cancer (CRC) mainly affects older patients. The pivotal VELOUR phase III trial of aflibercept plus FOLFIRI in metastatic CRC (mCRC) included only 5.9% of patients aged ≥75 years. Herein, we report a preplanned analysis from QoLiTrap, a large prospective observational study evaluating the impact of age on quality of life (QoL), effectiveness, and safety of aflibercept plus FOLFIRI in daily clinical practice in Europe. - Materials and Methods - Enrolled patients had progressive mCRC, had failed a prior oxaliplatin-based regimen, and had received aflibercept (4 mg/kg) plus FOLFIRI every two weeks until disease progression, death, unacceptable toxicity, or physician/patient decision. Analyses were performed by age classes (<60, 60-64, 65-69, 70-74, and ≥ 75 years). The primary endpoint was the percentage of patients whose global health status (GHS) of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) was maintained (i.e., no worsening from baseline by at least 5% over a 12-week treatment). Secondary endpoints included tumor objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. - Results - Overall, 1277 patients (<60 years, n = 327; 60-64 years, n = 231; 65-69 years, n = 227; 70-74 years, n = 259; and ≥ 75 years, n = 233) were treated, of whom 872 were evaluable for QoL. GHS was maintained in 36.5%, 41.6%, 38.9%, 41.8%, and 44.8% of patients aged <60, 60-64, 65-69, 70-74, and ≥ 75 years, respectively. Age did not influence PFS (median 7.8 months), OS (median 14.4 months), or ORR (20.8%). Number of cycles, dose delays for any cause, and dose reductions for adverse events (AEs) were comparable between age classes. Grade ≥ 3 AEs occurred in 47.7%, 51.9%, 51.5%, 55.2%, and 55.8% of patients aged <60, 60-64, 65-69, 70-74, and ≥ 75 years, respectively. The main grade ≥ 3 AEs were hypertension (11.2%) and diarrhea (9%) in patients aged ≥75 years. - Discussion - The results suggest that aflibercept plus FOLFIRI maintains QoL and retains its activity, including a high objective tumor response, regardless of age and treatment line. In fit older patients, the safety profile seems manageable, with no new safety signals. | ||
| 650 | 4 | |a Aflibercept | |
| 650 | 4 | |a Antiangiogenics | |
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a EGFR inhibitors | |
| 650 | 4 | |a Older adults | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a VEGF inhibitors | |
| 700 | 1 | |a Thaler, Josef |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anchisi, Sandro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geffriaud-Ricouard, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gueldner, Max |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scholten, Felicitas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Derigs, Hans-Günter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bohanes, Pierre |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grünberger, Birgit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schwarz, Leonora |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Moos, Roger |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of geriatric oncology |d Amsterdam [u.a.] : Elsevier Science, 2010 |g 14(2023), 8, Artikel-ID 101638, Seite 1-10 |h Online-Ressource |w (DE-627)627611915 |w (DE-600)2556813-9 |w (DE-576)336956584 |x 1879-4076 |7 nnas |a Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer an analysis of the prospective QoLiTrap study |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:8 |g elocationid:101638 |g pages:1-10 |g extent:10 |a Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer an analysis of the prospective QoLiTrap study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jgo.2023.101638 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1879406823002357 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240718 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 12 |y j | ||
| 999 | |a KXP-PPN1895740460 |e 4552989057 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer","title":"Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer","subtitle":"an analysis of the prospective QoLiTrap study"}],"origin":[{"dateIssuedDisp":"November 2023","dateIssuedKey":"2023"}],"recId":"1895740460","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Online verfügbar: 28. September 2023, Artikelversion: 28. September 2023","Gesehen am 18.07.2024"],"relHost":[{"part":{"issue":"8","extent":"10","pages":"1-10","text":"14(2023), 8, Artikel-ID 101638, Seite 1-10","year":"2023","volume":"14"},"language":["eng"],"title":[{"subtitle":"cancer and aging research","title":"Journal of geriatric oncology","title_sort":"Journal of geriatric oncology"}],"pubHistory":["1.2010 -"],"note":["Gesehen am 24.02.11"],"id":{"issn":["1879-4076"],"zdb":["2556813-9"],"eki":["627611915"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer an analysis of the prospective QoLiTrap studyJournal of geriatric oncology","origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"2010","publisher":"Elsevier Science","dateIssuedDisp":"2010-"}],"recId":"627611915","type":{"media":"Online-Ressource","bibl":"periodical"}}],"id":{"eki":["1895740460"],"doi":["10.1016/j.jgo.2023.101638"]},"physDesc":[{"extent":"10 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["Gudrun Piringer, Josef Thaler, Sandro Anchisi, Christine Geffriaud-Ricouard, Max Gueldner, Felicitas Scholten, Hans-Günter Derigs, Pierre Bohanes, Birgit Grünberger, Leonora Schwarz, Roger von Moos, Ralf-Dieter Hofheinz"]},"person":[{"family":"Piringer","given":"Gudrun","role":"aut","display":"Piringer, Gudrun"},{"given":"Josef","role":"aut","display":"Thaler, Josef","family":"Thaler"},{"role":"aut","given":"Sandro","display":"Anchisi, Sandro","family":"Anchisi"},{"family":"Geffriaud-Ricouard","role":"aut","given":"Christine","display":"Geffriaud-Ricouard, Christine"},{"display":"Gueldner, Max","given":"Max","role":"aut","family":"Gueldner"},{"display":"Scholten, Felicitas","role":"aut","given":"Felicitas","family":"Scholten"},{"role":"aut","given":"Hans-Günter","display":"Derigs, Hans-Günter","family":"Derigs"},{"family":"Bohanes","display":"Bohanes, Pierre","role":"aut","given":"Pierre"},{"given":"Birgit","role":"aut","display":"Grünberger, Birgit","family":"Grünberger"},{"family":"Schwarz","display":"Schwarz, Leonora","given":"Leonora","role":"aut"},{"display":"von Moos, Roger","given":"Roger","role":"aut","family":"von Moos"},{"family":"Hofheinz","display":"Hofheinz, Ralf-Dieter","role":"aut","given":"Ralf-Dieter"}]} | ||
| SRT | |a PIRINGERGUQUALITYOFL2023 | ||